Cargando…
Translational neuroimmunology in multiple sclerosis : from disease mechanisms to clinical applications /
Multiple sclerosis (MS) is the most common disabling neurological disease of young adults. More than 2.3 million people are affected by MS worldwide. Symptoms can vary widely, depending on the localization and amount of the damage induced by combined inflammatory, demyelinating, and neurodegenerativ...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam :
Academic Press is an imprint Elsevier,
[2016]
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn949884227 | ||
| 003 | OCoLC | ||
| 005 | 20231120112109.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 160517t20162016ne a ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d IDEBK |d EBLCP |d N$T |d OPELS |d OCLCF |d YDXCP |d OCLCQ |d OTZ |d OCLCQ |d U3W |d D6H |d CEF |d OCLCQ |d WYU |d LQU |d OCLCQ |d UKMGB |d S2H |d OCLCO |d LVT |d OCLCO |d OCLCQ | ||
| 015 | |a GBB670168 |2 bnb | ||
| 016 | 7 | |a 017857229 |2 Uk | |
| 019 | |a 949988309 |a 1066599137 |a 1105194580 |a 1105567307 |a 1229756498 | ||
| 020 | |a 9780128020074 |q (electronic bk.) | ||
| 020 | |a 0128020075 |q (electronic bk.) | ||
| 020 | |z 9780128019146 | ||
| 020 | |z 012801914X | ||
| 035 | |a (OCoLC)949884227 |z (OCoLC)949988309 |z (OCoLC)1066599137 |z (OCoLC)1105194580 |z (OCoLC)1105567307 |z (OCoLC)1229756498 | ||
| 050 | 4 | |a RC377 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.834 |2 23 |
| 245 | 0 | 0 | |a Translational neuroimmunology in multiple sclerosis : |b from disease mechanisms to clinical applications / |c edited by Ruth Arnon, Ariel Miller. |
| 264 | 1 | |a Amsterdam : |b Academic Press is an imprint Elsevier, |c [2016] | |
| 264 | 4 | |c �2016 | |
| 300 | |a 1 online resource : |b color illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Online resource; title from PDF title page (EBSCO, viewed June 15, 2016). | |
| 520 | |a Multiple sclerosis (MS) is the most common disabling neurological disease of young adults. More than 2.3 million people are affected by MS worldwide. Symptoms can vary widely, depending on the localization and amount of the damage induced by combined inflammatory, demyelinating, and neurodegenerative processes. Although a cure for MS does not currently exist, therapies can help treat MS attacks, attenuate disease activity, reduce progress of the disease, and manage symptoms. Translational Neuroimmunology in Multiple Sclerosis provides an overview of recent findings and knowledge of the neuroimmunology of multiple sclerosis, from experimental models and the human disease to the translation of this research to immunotherapeutic strategies. Chapters describe genetic and environmental factors underlying the disease pathogenesis of MS as a basis for development of immunotherapies, immunological markers of disease activity, pharmacogenetics, and responses to therapy. Immunomodulatory therapies currently in practice and future therapeutic strategies on the horizon-such as neuroprotective strategies, stem cells, and repair promotion-are discussed. Contributed by renowned leaders in the field, this cross-disciplinary volume is a great resource for basic scientists and clinical practitioners in neuroscience, neurology, immunology, pharmacology, and in-drug development. | ||
| 505 | 0 | |a <P><b>Section I: MS Pathology and Mechanisms </b>1. MS Pathology: Inflammation versus Neurodegeneration 2. Immune Dysregulation in Multiple Sclerosis 3. CNS immune regulation 4. Genetics of Multiple Sclerosis 5. MS Subtypes: How the Natural History of MS was Challenged Due to Treatment 6. Pediatric-Onset MS as a Window into Early Disease Targets and Mechanisms 7. Sex-related factors in multiple sclerosis</p> <p><b>Section II: Other Patho-Mechanisms </b>8. Environmental Factors and their regulation of immunity in MS 9. Gut Microbiota in Multiple Sclerosis: A Bioreactor driving Brain Autoimmunity 10. Glutamate and Multiple Sclerosis: glutamate receptors and effects in the CNS, glutamate receptors and direct effects on T cells, and contribution of both to Multiple Sclerosis 11. Dopamine, T cells and Multiple Sclerosis: Dopamine receptors and direct effects on T cells, dopamine production in T cells, abnormalities in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis, and their correction by treatment 12. Neuroendocrine Checkpoints of Innate Immune Responses in Multiple Sclerosis: Reciprocal Interactions between Body and Brain 13. Fighting chronic neuroinflammation by boosting autoimmunity: the distinction between neurodegenerative diseases and multiple sclerosis 14. Neuroactive steroids and Neuroinflammation</p> <p><b>Section III: Surrogate Markers in Multiple Sclerosis </b>15. Surrogate Markers in Multiple Sclerosis: The Role of MRI</p> <p><b>Section IV: Currently Approved Therapies -- Injectable </b>16. Interferon � in Multiple Sclerosis: A Review 17. Glatiramer Acetate -- From Bench to Bed and Back 18. Natalizumab 19. Alemtuzumab (Campath-1H) 20. Currently approved DMDs-injectable: cytotoxic immunosuppressive drugs</p> <p><b>Section V: Currently Approved DMDs -- Oral </b>21. Fingolimod (Gilenya) 22. Oral Dimethyl Fumarate (BG-12; Tecfidera�) for Multiple Sclerosis 23. Emerging MS Therapies in the Horizon</p> <p><b>Section VI: Symptomatic and Complementary Treatments </b>24. Treatment of acute relapses in Multiple sclerosis 25. Shedding light on Vitamin D and MS 26. Symptomatic and Complementary Treatments 27. Cognitive Impairment in Multiple Sclerosis</p> <p><b>Section VII. Novel & Emerging Strategies </b>28. Personalized Medicine and Theranostics: Applications to Multiple Sclerosis 29. Stem cell based-therapies, remyelination and repair promotion, in the treatment of multiple sclerosis 30. Stem cells in Multiple Sclerosis 31. T cell vaccination: An insight into T cell regulation 32. Reversal of Misfortune: Therapeutic Strategies on the Horizon</p> | |
| 650 | 0 | |a Multiple sclerosis. | |
| 650 | 0 | |a Neuroimmunology. | |
| 650 | 2 | |a Multiple Sclerosis |0 (DNLM)D009103 | |
| 650 | 2 | |a Neuroimmunomodulation |0 (DNLM)D015213 | |
| 650 | 6 | |a Scl�erose en plaques. |0 (CaQQLa)201-0052729 | |
| 650 | 6 | |a Neuro-immunologie. |0 (CaQQLa)201-0135586 | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Multiple sclerosis. |2 fast |0 (OCoLC)fst01029018 | |
| 650 | 7 | |a Neuroimmunology. |2 fast |0 (OCoLC)fst01036361 | |
| 700 | 1 | |a Arnon, R., |e editor. | |
| 700 | 1 | |a Miller, Ariel, |e editor. | |
| 776 | 0 | 8 | |i Print version: |t Translational neuroimmunology in multiple sclerosis. |d �2016 |z 9780128019146 |z 012801914X |w (OCoLC)891125399 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780128019146 |z Texto completo |